businessbriefs
10:01in productionCh. 1 · The First Factory/ 10:01 · ceiling 15 min
Company stories

Johnson & Johnson

A medical supply company that sold authority before it sold medicine.

Johnson & Johnson began as a vertically integrated supplier of standardised, sterile medical consumables — selling trust, training, and readiness, not cures.

Chapters & takeaways4
  1. 1:12
    The First Factory

    Fourteen people launched a factory to make sterile dressings — not as a hospital supplier, but as a new category creator.

  2. 2:53
    The Railroad Kit

    The first commercial first aid kit was a logistics solution for workers hundreds of miles from care — not a consumer product.

  3. 4:04
    The Guide as Infrastructure

    Distributing 85,000 surgical guides wasn’t marketing — it was credentialing the company as the source of best practice.

  4. 5:28
    Science for Distribution

    Hiring a scientific director in 1889 meant research served sales — writing manuals, not discovering molecules.

Worth your time?

Yes. Study the whole thing.

4.5/ 5
What works
  • standardisation as market creation
  • distribution as authority
  • manuals as infrastructure
What does not
  • pharmaceuticals
  • biotechnology
  • medical devices
Study it if
  • historians of business
  • product strategists
  • healthcare infrastructurists
Skip it if
  • investors assessing current J&J valuation
  • biotech founders seeking drug development playbooks
The written brief1 min read

What the company or idea is

Johnson & Johnson was a New Brunswick–based manufacturer of ready-to-use sterile surgical dressings, first aid kits, and educational surgical guides, founded in 1886 by Robert Wood Johnson and his brothers.

How it actually makes money

It sold sterile surgical dressings, first aid kits, and medical guides — not through prescriptions or insurers, but directly to doctors, pharmacists, and employers like railroads.

What works

Publishing and distributing 85,000 surgical guides in 1888 established credibility with doctors and pharmacists. Designing a first aid kit for remote railroad workers created demand where no medical infrastructure existed.

What does not

The material says nothing about pharmaceuticals, biotechnology, or medical devices — those came later. The 1886 company did not treat disease, develop drugs, or conduct clinical trials.

What to take from it

Its early model relied on standardisation, distribution leverage, and authority-building — not innovation for its own sake, but for adoption by gatekeepers who controlled access to care.

Is it worth your time

Yes — as a case study in how a company built scale before regulation, patents, or mass advertising by embedding itself in professional practice and infrastructure.

Same desk · Company stories4 of 18
10:48
Norsk HydroKristian Birkeland · 1905Norsk Hydro began as a single-purpose vehicle for Birkeland’s nitrogen-fixing arc — a physics experiment turned factory. Its early dominance came not from IP or management, but from locking in Norway’s hydropower geography. It survived obsolescence not through reinvention, but by ceding chemical control to IG Farben. Its WWII role — sole European heavy water producer — was accidental infrastructure reuse. Its current aluminium and renewables business shares no technology with its origin, only its dams, debt, and place.
10:07
PeterbiltT.A. Peterman · 1939Peterbilt is a case study in acquisition-led industrial continuity: a timber operator bought a defunct truck maker to solve local hauling problems, engineered narrowly effective solutions, scaled only when external demand (military) appeared, and exited when land value exceeded truck value. Its legacy lies in execution, not vision.
10:34
Akio MoritaSony’s origin story is not about genius invention but calculated access: to Bell Labs’ transistors, to CBS’s content pipeline, to NYSE capital markets. Its early wins came from treating technology as licensable infrastructure, not proprietary magic. Its Betamax loss confirms that even first-mover advantage collapses without partner economics aligned.
10:04
BPWilliam Knox D'Arcy · 1908BP’s origin story is not about entrepreneurship or engineering — it is about a sovereign concession enabling extraction. Its business model depends on controlling physical assets and political access, not market creation or product innovation.
Up next in Business

Travis Kalanick

· 9:40

Travis Kalanick doesn’t build platforms — he exploits regulatory silence until the law catches up, then pivots to the newly legal version.

9:40